NCT03374020

Brief Summary

Comparison between retinal measurements, done by the Notal-OCT imaging and a commercial OCT (Optical Coherence Tomography)

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2017

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 17, 2017

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

September 11, 2017

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 14, 2017

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 14, 2018

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

November 13, 2020

Status Verified

October 1, 2020

Enrollment Period

1.3 years

First QC Date

September 11, 2017

Last Update Submit

November 11, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • The level of agreement between NOTAL-OCT and commercial OCT in detecting fluid in the 10 central degrees of the macula.

    OCT B-scans from both devices will be graded for fluid by an eye care professional and results per macula will be analyzed. A binary decision "there is fluid" or "there is no fluid" will be given to each macula (10 central degrees). Then agreement between decisions, commercial and Notal OCT, will be compared

    1 year

Study Arms (4)

Intermediate AMD

Device: Notal OCT

Advanced AMD

Device: Notal OCT

DR without macular edema

Device: Notal OCT

DR with macular edema

Device: Notal OCT

Interventions

Notal OCTDEVICE

Imaging using Notal OCT

Advanced AMDDR with macular edemaDR without macular edemaIntermediate AMD

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

1. AMD population - intermediate and advanced AMD (with active and non-active CNV) 2. DR population. Patient with and without DME

You may qualify if:

  • Ability and agreement to give informed consent (IC)
  • Diagnosis of AMD or DR in SE by OCT
  • Ability to undergo OCT scans
  • VA of 20/160 or better in SE

You may not qualify if:

  • AMD and DR in the same SE
  • Evidence of macular disease other than AMD or DME in SE

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Macular DegenerationDiabetic Retinopathy

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 11, 2017

First Posted

December 14, 2017

Study Start

January 17, 2017

Primary Completion

May 14, 2018

Study Completion

December 1, 2018

Last Updated

November 13, 2020

Record last verified: 2020-10